



Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma

Jan Budczies^{1,2,3} · Martina Kirchner¹ · Klaus Kluck^{1,2} · Daniel Kazdal^{1,3} · Julia Glade¹ · Michael Allgäuer¹ · Mark Kriegsmann^{1,3} · Claus-Peter Heußel^{3,4,5} · Felix J. Herth^{3,6} · Hauke Winter^{3,7} · Michael Meister^{3,8} · Thomas Muley^{3,8} · Torsten Goldmann^{9,10} · Stefan Fröhling^{2,11} · Martin Wermke¹² · Cornelius F. Waller¹³ · Amanda Tufman¹⁴ · Martin Reck^{10,15} · Solange Peters¹⁶ · Peter Schirmacher^{1,2} · Michael Thomas^{3,17} · Petros Christopoulos^{3,17} · Albrecht Stenzinger^{1,2,3}

Received: 5 December 2020 / Accepted: 4 June 2021 / Published online: 14 June 2021
© The Author(s) 2021

Abstract

Introduction The advent of immune checkpoint blockade (ICB) has led to significantly improved disease outcome in lung adenocarcinoma (ADC), but response of ALK/EGFR-positive tumors to immune therapy is limited. The underlying immune biology is incompletely understood.

Methods We performed comparative mRNA expression profiling of 31 ALK-positive, 40 EGFR-positive and 43 ALK/EGFR-negative lung ADC focused on immune gene expression. The presence and levels of tumor infiltration lymphocytes (TILs) as well as fourteen specific immune cell populations were estimated from the gene expression profiles.

Results While total TILs were not lower in ALK-positive and EGFR-positive tumors compared to ALK/EGFR-negative tumors, specific immunosuppressive characteristics were detected in both subgroups: In ALK-positive tumors, regulatory T cells were significantly higher compared to EGFR-positive (fold change: FC = 1.9, $p = 0.0013$) and ALK/EGFR-negative tumors (FC = 2.1, $p = 0.00047$). In EGFR-positive tumors, cytotoxic cells were significantly lower compared to ALK-positive (FC = -1.7, $p = 0.016$) and to ALK/EGFR-negative tumors (FC = -2.1, $p = 2.0E-05$). A total number of 289 genes, 40 part of cytokine–cytokine receptor signaling, were differentially expressed between the three subgroups. Among the latter, five genes were differently expressed in both ALK-positive and EGFR-positive tumors, while twelve genes showed differential expression solely in ALK-positive tumors and eleven genes solely in EGFR-positive tumors.

Conclusion Targeted gene expression profiling is a promising tool to read out tumor microenvironment characteristics from routine diagnostic lung cancer biopsies. Significant immune reactivity including specific immunosuppressive characteristics in ALK- and EGFR-positive lung ADC, but not a total absence of immune infiltration supports further clinical evaluation of immune-modulators as partners of ICB in such tumors.

Keywords Lung adenocarcinoma · ALK fusion · EGFR mutation · Immunotherapy · Immune checkpoint blockade · Immunosuppression

Abbreviations

ADC	Adenocarcinoma	ALK/EGFR-negative tumor	Tumor that is neither ALK-positive nor EGFR-positive
ALK-positive tumor	Tumor with activating ALK gene fusion	EGFR-positive tumor	Tumor with activating somatic mutation in EGFR
		FC	Fold change
		ICB	Immune checkpoint blockade
		LTR	Long-term responders (at least one year after start of ICB)
		NSCLC	Non-small cell lung cancer

Co-first authors: Jan Budczies, Martina Kirchner, Klaus Kluck
Co-last authors: Petros Christopoulos, Albrecht Stenzinger

✉ Jan Budczies
jan.budczies@med.uni-heidelberg.de

Extended author information available on the last page of the article

RP	Rapid progressors (within two months after start of ICB)
rho	Spearman correlation coefficient
TILs	Tumor-infiltrating lymphocytes
TKI	Tyrosine kinase inhibitor
TMB	Tumor mutational burden
TME	Tumor microenvironment
Tregs	Regulatory T cells

Introduction

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide [1]. Despite major advances in therapeutic options, the majority of patients are diagnosed at advanced stage with a median survival rate below 2 years. Genetic profiling is of key importance for treatment decision in NSCLC, since targeted therapies, mainly tyrosine kinase inhibition (TKI), have shown dramatically superior efficacy as compared to standard of care chemotherapy in oncogene-addicted tumors [2]. EGFR mutations and ALK fusions represent the most frequent targetable alterations with a prevalence of, respectively, 10–20% and 3–5% in a Caucasian population with lung adenocarcinomas (ADC) [3].

While the advent of immune checkpoint blockade (ICB) led to significant advances in disease control and survival of driver-negative NSCLC, it quickly became apparent that ALK- and EGFR-positive tumors show limited response to ICB. For example, even despite encouraging early results from the Keynote-001 trial suggesting potential efficacy of pembrolizumab in TKI-naïve EGFR-mutated NSCLC, these were invalidated in a subsequent phase 2 trial [4, 5]. Similarly, Checkmate 012 [6], a phase 1 trial investigating first-line nivolumab monotherapy or in combination with standard therapies for NSCLC demonstrated no meaningful activity in EGFR-mutated tumors. The same trial also investigated the combination of nivolumab with platinum-based chemotherapy and showed reduced activity in EGFR-mutant compared to EGFR-wildtype tumors [7]. Furthermore, several clinical trials combining ICB and TKI resulted in significant toxicity without a signal of improved activity above TKI [7–9]. The only exception so far has been the IMpower150 study, which demonstrated a survival benefit for TKI-pretreated patients with ALK/EGFR-positive NSCLC when the PD-L1 inhibitor atezolizumab was combined with both the antiangiogenic agent bevacizumab and chemotherapy [10, 11].

The biological underpinnings for ICB primary resistance in patients with EGFR-/ALK-positive NSCLC are

incompletely understood. Lower tumor mutational burden (TMB), for example, in tumors of never smokers [12, 13], a different nature of PD-L1 expression (intrinsic, induced by oncogenic signaling rather than tumor-infiltrating lymphocytes) [14, 15] and features of the tumor microenvironment (TME) [16–19], possibly influenced by MAPK-signaling [20], have all been suggested as potential causes. The TME is increasingly recognized as crucial parameter for the efficacy of immunotherapies in general, but biological data, especially for the less frequent ALK-positive tumors, are limited [21].

We employed the NanoString nCounter technology and the PanCancer Human IO 360 Panel to investigate the TME in 114 formalin-fixed and paraffin-embedded (FFPE) biopsies of clinically annotated ALK-positive, EGFR-positive and ALK/EGFR-negative advanced lung ADC. We also analyzed gene expression data of earlier stage, resectable tumors from the TCGA lung ADC cohort.

Material and methods

Study cohort

The retrospective study cohort included 31 ALK-positive, 40 EGFR-positive and 43 ALK/EGFR-negative lung ADC patients diagnosed and treated at the Heidelberg University Hospital between 2007 and 2020 (Table 1). ALK and EGFR status were determined at the Heidelberg Institute of Pathology using our routine diagnostic workflow of combined DNA and RNA sequencing starting from formalin-fixed and paraffin-embedded (FFPE) lung biopsies [22]. Tumors harboring activating EGFR mutations were classified as EGFR-positive, and tumors harboring oncogenic ALK fusions were classified as ALK-positive (Suppl. 1).

EGFR/ALK-positive patients were therapy-naïve, i.e., received neither TKI nor chemo- or immunotherapy prior to biopsy. ALK/EGFR-negative patients underwent biopsy immediately before start of ICB treatment and were further subdivided according to the subsequent ICB response in 16 long-term responders (LTR; durable response to ICB of 12 months or more), 21 rapid progressors (RP; disease progression within two months of ICB start) and 6 patients with an intermediate duration of response to ICB (IR). For all patients, only biopsies from the primary (lung) tumor with sufficient available mRNA for expression profiling were analyzed. The study was approved by the ethics committee of Heidelberg University (S-145/2017). The subcohort of ALK/EGFR-negative tumors was also analyzed in a study comparing the gene expression differences between LTR and RP [23].

Table 1 Clinicopathological characteristics of the study cohort comprising 114 lung adenocarcinomas

Mutation subtype	ALK-positive	EGFR-positive	ALK/EGFR-negative
Number	31	40	43
Age: median (min.- max.)	58 (33–90)	69.5 (46–83)	64 (41–89)
Sex:			
Male	15 (48%)	7 (18%)	21 (49%)
Female	16 (52%)	33 (83%)	22 (51%)
Smoking history:			
Smoker	9 (29%)	15 (38%)	41 (95%)
Non-smoker	17 (55%)	25 (63%)	2 (5%)
Unknown	5 (16%)	0 (0%)	0 (0%)
Tumor stage:			
I	0 (0%)	0 (0%)	0 (0%)
II	1 (3%)	4 (10%)	0 (0%)
III	7 (23%)	10 (25%)	0 (0%)
IV	23 (74%)	26 (65%)	43 (100%)
Prior therapy:			
Naïve	31 (100%)	40 (100%)	26 (60%)
Chemotherapy	0 (0%)	0 (0%)	17 (40%)
Response to ICB	no ICB	no ICB	16 LTR [*] , 6 IR [†] , 21 RP [‡]

*Long-term responders

†Intermediate progressors

‡Rapid progressors

TCGA lung adenocarcinoma cohort

Gene expression and clinical data of the TCGA lung ADC cohort (LUAD) were downloaded from the PanCanAtlas webpage of the Genomic Data Commons repository (<https://gdc.cancer.gov/about-data/publications/pancanatlas>). Only samples diagnosed as lung adenocarcinoma and of the type “primary solid tumor” (code: 01) were included. Information on ALK fusion status was obtained from a gene fusion analysis based on RNA-Seq data [24]. The TCGA cohort included 5 ALK-positive, 57 EGFR-positive and 439 ALK/EGFR-negative lung ADC (Suppl. 2).

Targeted gene expression profiling

Targeted mRNA expression profiling was conducted on the NanoString nCounter gene expression platform (NanoString Technologies, Seattle, WA) using a 770-gene panel (PanCancer Human IO 360 Panel) focused on genes connected with the interplay between tumor, tumor microenvironment and immune response in cancer. Per sample, 100 ng of total RNA in a final volume of 5 µl was mixed with a 3' biotinylated capture probe and a 5' reporter probe tagged with a fluorescent barcode sequence from the PanCancer IO 360 gene expression code set. Probes and target transcripts were hybridized at 65 °C for 18 h according to the manufacturer's recommendations. Hybridized samples were run on the NanoString nCounter preparation station

using the high-sensitivity protocol, in which excess capture and reporter probes are removed and transcript-specific complexes are immobilized on a streptavidin-coated cartridge. The samples were scanned at maximum resolution on the nCounter Digital Analyzer.

Immunohistochemistry

For detection of FOXP3 and CD8 protein expression, 3 µm thick paraffin sections were prepared. Deparaffinization and tissue staining were performed using a Benchmark Ultra IHC Staining module according to standard protocols (FOXP3 Monoclonal Antibody, clone 236A/E7, eBioscience, Invitrogen, Thermo Fisher Scientific Inc., Waltham, MA and CONFIRM anti-CD8 Rabbit Monoclonal Primary Antibody, clone SP57, Roche, Mannheim, Germany). Staining was visualized using the Vectastain elite ABC detection system (Vector, Burlingame, CA, USA) and using 3,3'-Diaminobenzidine (Optiview DAB IHC Detection Kit or ultraView Universal DAB Detection Kit, Ventana, Roche, Mannheim, Germany) as chromogen. Hematoxylin was used for counterstaining of cell nuclei. Evaluation and scoring were performed by an expert pathologist using the image analysis software QuPath (Open Source Digital Pathology, <https://github.com/qupath>).

Data analysis

Statistical analysis was performed using the programming language R. Sample normalization of the gene expression data was performed by fitting a linear model to negative and positive controls and subsequent housekeeping gene normalization. For the latter, the 20 panel genes with the lowest coefficient of variation and an expression level of at least 100 in the TCGA lung ADC dataset were used as housekeepers (*AKT1*, *API5*, *DNAJC14*, *EIF2B4*, *ELA*, *ERCC3*, *GLUD1*, *HDAC3*, *HMGB1*, *IFNAR1*, *MLH1*, *OAZ1*, *PUM1*, *RIPK1*, *SF3A1*, *STAT3*, *TBC1D10B*, *TLK2*, *TMUB2* and *UBB*). The gene expression profile of each sample was scaled by the median expression level of the housekeeping genes. Gene expression data were log₂-transformed prior to statistical analysis and visualization.

The abundance of 14 immune cell populations (B cells, CD45+ cells, CD56dim NK cells, CD8+ T cells, cytotoxic cells, dendritic cells, exhausted CD8+ T cells, macrophages, mast cells, neutrophils, NK cells, T cells, Th1 cells and Treg cells) was estimated from the mRNA expression of marker genes as described and validated before [25]. The abundance of cell populations was reported on log₂ scale. The “immunological distance” between two tumors was defined as the Manhattan distance between in the space of the 14 immune cell populations. Analyses were carried out on the following two levels: (1) on the level of the abundance of 14 immune cell populations and (2) on the level of the mRNA expression of 770 genes.

For heatmap displays, each of the cell populations (or genes) was centered (but not scaled) with respect to the mean abundance (or mean mRNA expression) over the samples. Hierarchical clustering was performed using Pearson correlations as similarity measure and the average linkage as measure of distances between clusters. Correlations between clusters and genetic subgroups were assessed using Fisher’s exact test.

Differences between ALK-positive, EGFR-positive and ALK/EGFR-negative tumors were assessed for significance using the Kruskal–Wallis as omnibus test and the Wilcoxon test as post hoc test. The Benjamini–Hochberg procedure was used for p value correction, and lists of cell populations or genes were compiled controlling the false discovery rate (FDR) at 5%. KEGG Mapper was used to visualize the cytokine–cytokine receptor network (pathway hsa04060) [26].

Results

The study cohort comprised 31 ALK-positive, 40 EGFR-positive and 43 ALK/EGFR-negative lung ADC patients (Table 1). Biopsies of each of the 114 primary tumors

underwent gene expression profiling with an assay of 770 genes focused on immune-related genes. The abundance of 14 immune cell populations in the TME was estimated using an already established method [25].

Overall level of immune cell infiltration

The levels of the immune cell populations were grouped by hierarchical clustering and visualized in a heatmap (Fig. 1a). The markers of cytotoxic cells, T cells, CD8+ T cells and exhausted CD8+ T cells clustered tightly together (all pairwise Spearman correlations $\rho > 0.77$). Moreover, macrophages and CD45+ cells showed a strong positive correlation ($\rho = 0.67$). The tumors clustered together in two main immunological groups, “cold” tumors ($n = 58$) and “hot” tumors ($n = 56$). The immunological groups did not correlate with the mutation type (ALK-positive, EGFR-positive or ALK/EGFR-negative) of the tumors ($p = 0.82$). Furthermore, the immunological groups did neither correlate with the type of ALK fusion (V1 vs. V3, $p = 1$) nor with the type of EGFR mutation (Ex19del vs. L858R, $p = 0.69$).

In line with the cluster analysis, neither the levels of CD45+ cells nor of total TILs (calculated as in [25]) correlated with the mutation type ($p = 0.47$ and $p = 0.11$). Additionally, we split the ALK/EGFR-negative tumors in long-term responders (LTR) and in rapid progressors (RP) with respect to ICB and carried out a four-group-analysis of ALK-positive tumors, EGFR-positive tumors, LTR and RP. Both, CD45+ cells and total TILs were significantly higher in LTR, but not in RP compared to EGFR-positive tumors (Fig. 1b, c). Neither CD45+ cells nor total TILs showed significant differences when comparing LTR or RP with ALK-positive tumors.

To test whether ALK/EGFR-positive tumors are “immunologically closer” to RP than to LTR, we operationalized the concept of immunological similarity by the introduction of an immunological distance based on the abundance of the 14 immune cell populations. It turned out that both ALK-positive tumors and EGFR-positive tumors were significantly closer to LTR than to RP tumors falsifying the hypothesis (Suppl. 3). This observation suggested distinct rather than common immunosuppressive features of the three subgroups, a hypothesis that we further addressed by comparative analyses of immune cell populations and gene expression profiles between the subgroups.

Specific immune cell populations

Seven of 14 immune cell populations were significantly different in ALK-positive, EGFR-positive and ALK/EGFR-negative tumors using omnibus testing (Fig. 2a, marked by*). Regulatory T cells (Tregs) were significantly higher in ALK-positive tumors compared to ALK/EGFR-negative




Fig. 1 Immunological analysis of 114 lung adenocarcinomas by targeted gene expression profiling. **a** Clustering of the tumors by the abundance of 14 immune cell populations. **b** CD45+ cells were higher in EGFR/ALK-negative tumors that showed durable ICB response (long-term responders, LTR) compared to EGFR/ALK-negative tumors that progressed rapidly (rapid progressors, RP)

and compared to EGFR-positive tumors. Levels of CD45+ cells between ALK-positive, EGFR-positive and rapid progressing ALK/EGFR-negative tumors did not differ significantly. IR=intermediate responders. **c** Similar as in B but for total TILs. Distributions are shown with median, lower and upper quartile

tumors ($FC = 2.1, p = 0.00047$). Cytotoxic cells, CD8+ T cells and exhausted CD8+ T cells were significantly lower in EGFR-positive tumors compared to ALK/EGFR-negative tumors ($FC = -2.1, p = 1.1E-05$; $FC = -1.9, p = 0.0037$ and $FC = -1.6, p = 0.0045$). Here, ‘cytotoxic cells’ (markers genes: *PRF1, GZMA, GZMB, GZMH, GNLY, CTSW, KLRB1, KLRD1, KLRK1* and *NKG7*) refer to a broader cell

population of granzyme releasing cells including cytotoxic T cell and cytotoxic NK cells compared to the more specific population of ‘CD8+ T cells’ (marker genes: *CD8A* and *CD8B*). Tregs, neutrophils, cytotoxic cells, exhausted CD8+ T cells and macrophages were significantly higher in ALK-positive compared to EGFR-positive tumors ($FC = 1.9, p = 0.0013$; $FC = 1.8, p = 0.00078$; $FC = 1.7, p = 0.015$;




Fig. 2 Levels of specific immune cell populations differ between ALK-positive, EGFR-positive and ALK/EGFR-negative lung adenocarcinomas. **a** Significantly higher Tregs in ALK-positive tumors compared to ALK/EGFR-negative tumors. Significantly lower cytotoxic cells, CD8+ T cells and exhausted CD8+ T cells in EGFR-positive tumors compared to ALK/EGFR-negative tumors. Significantly higher Tregs cells, neutrophils, macrophages, exhausted CD8+ T cells and cytotoxic cells in ALK-positive compared to EGFR-positive

tumors. *=significant in omnibus test. **b** Significantly higher regulatory T cells in ALK-positive tumors compared to EGFR-positive tumors and to ALK/EGFR-negative tumors that progressed rapidly or intermediately after ICB. **c** Significantly lower cytotoxic cells in EGFR-positive tumors compared to ALK-positive tumors, to ALK/EGFR-negative tumors that showed durable ICB response and to ALK/EGFR-negative tumors that progressed rapidly under ICB

FC = 1.6, $p = 0.017$ and FC = 1.5, $p = 0.00074$). Thus, ALK-positive tumors stood out by significantly higher Tregs compared to EGFR-positive and ALK/EGFR-negative tumors, while EGFR-positive tumors stood out by significantly lower

cytotoxic cells and exhausted CD8+ T cells compared to the two other subgroups.

In two more analyses, we investigated subgroups of the ALK/EGFR-negative tumors that were homogeneous

regarding (1) prior treatment, (2) the duration of response to immune therapy, (3) smoking history and (4) TP53 mutation status. Firstly, the results obtained for the complete group of ALK/EGFR-negative tumors stayed correct for the subgroup of treatment-naïve tumors: Tregs were higher in ALK-positive cancer compared to treatment-naïve ALK/EGFR-negative cancer ($FC = 2.3$, $p = 0.00015$). Cytotoxic cells, CD8+ T cells and exhausted CD8+ T cells were lower in EGFR-positive cancer compared to treatment-naïve ALK/EGFR-negative cancer ($FC = -2.2$, $p = 4.1E-05$; $FC = -2.0$, $p = 0.01$ and $FC = -1.7$, $p = 0.0082$). Secondly, the group of ALK/EGFR-negative tumors was split in long-term responders (LTR) and rapid progressors (RP) under ICB (Fig. 2b, c, Suppl. 4). Tregs were significantly higher in ALK-positive tumors compared to RP ($FC = 2.9$, $p = 0.00069$), while a non-significant trend to higher levels ($FC = 1.4$, $p = 0.094$) was observed in comparison to LTR. Cytotoxic cells were significantly lower in EGFR-positive tumors compared to both RP and LTR ($FC = -1.9$, $p = 0.0043$ and $FC = -2.9$, $p = 1.6E-06$). Thirdly, levels of Tregs and cytotoxic cells did not differ significantly between smokers and non-smokers, while Tregs were enhanced in both ALK-positive tumors of smokers and non-smokers and cytotoxic cells were depleted in both EGFR-positive tumors of smokers and non-smokers (Suppl. 5A/B). Likewise, TP53 mutations did not confound the regulation patterns of Tregs and cytotoxic cells detected in the study cohort (Suppl. 5C/D).

Next, we investigated the validity of the findings in a cohort of earlier lung ADC (Suppl. 2). Of the three immune cell populations that were significantly reduced in EGFR-positive tumors compared to ALK/EGFR-negative tumors, the reduction of cytotoxic cells and CD8+ T was also found in the TCGA cohort ($FC = -1.6$, $p = 0.015$ and $FC = -1.6$, $p = 0.0018$). A significantly higher abundance of Tregs in ALK-positive tumors was not detected in the TCGA cohort, but this analysis was heavily underpowered with only five ALK-positive cases available.

FOXP3 and CD8 protein expression

Representative example cases of the study cohort were analyzed using immunohistochemistry (Fig. 3). FOXP3 and CD8 protein expression were quantified by counting the positive cells in relation to all cells (tumor, immune and other cells) in the tissue section. The percentage of FOXP3-positive cells was lower than 4% in all of the twenty analyzed cases. We observed a diffuse distribution FOXP3-positive immune cells in the intra- and peritumoral stroma, while we did not observe any clusters of two or more adjacent FOXP3-positive cells. The percentage of FOXP3 was significantly higher ($p = 0.029$) in the ALK-positive cases (mean: 1.84%) compared to the ALK-negative cases (mean: 0.96%). The percentage of CD8-positive cells ranged between virtually

0% and 60% in the ten analyzed example cases. CD8-positive immune cells showed formation of small groups as well as of larger dense clusters. The percentage of CD8-positive cells was significantly lower ($p = 0.0065$) in the EGFR-positive cases (mean: 9%) compared to the EGFR-negative cases (mean: 40%). Altogether, the protein expression analysis confirmed enrichment of FOXP3-positive cells in ALK-positive cancer and depletion of CD8-positive cells in EGFR-positive cancer.

PD-L1 expression


Levels of *PD-L1* mRNA were analyzed in a four-group-analysis (Fig. 4a). *PD-L1* mRNA expression was significantly lower in EGFR-positive tumors compared to the ALK-positive tumors ($FC = -1.8$, $p = 0.00073$) and compared to both groups of ALK/EGFR-negative tumors (LTR: $FC = -2.7$, $p = 0.00077$; RP: $FC = -2.0$, $p = 0.01$). Significant positive correlations with *PD-L1* mRNA expression were observed for eight of the 14 immune cell populations, namely for cytotoxic cells ($\rho = 0.45$), CD8+ T cells ($\rho = 0.38$), exhausted CD8+ cells ($\rho = 0.34$), neutrophils ($\rho = 0.33$), T cells ($\rho = 0.32$), Th1 cells ($\rho = 0.31$), dendritic cells ($\rho = 0.3$) and Treg cells ($\rho = 0.28$).

Thus, by far the strongest correlation was observed between *PD-L1* mRNA and cytotoxic cells (Fig. 4b). Partly, this correlation was induced by the incidence of low *PD-L1* expression and low abundance of cytotoxic cells in EGFR-positive tumors and at the same time higher levels of both markers in ALK-positive and ALK/EGFR-negative tumors. Additionally, *PD-L1* expression and cytotoxic cells correlated positively within some of the subgroups, namely in ALK-positive tumors ($\rho = 0.45$, $p = 0.012$) and in ALK/EGFR-negative tumors ($\rho = 0.36$, $p = 0.02$), but not EGFR-positive tumors where the correlation was not significant.

Gene expression analysis

In omnibus testing, 289 of 770 investigated genes showed significantly different expression levels in ALK-positive, EGFR-positive and ALK/EGFR-negative tumors (FDR = 5%, Suppl. 6). In detail, 145 genes were differentially expressed between ALK-positive and ALK/EGFR-negative tumors, 122 genes were differentially expressed between EGFR-positive and ALK/EGFR-negative tumors, and 192 genes were differentially expressed between ALK-positive and EGFR-positive tumors. The results could be partially confirmed by analyzing the independent TCGA cohort of early stage lung ADC with a match of 44 genes (30%), 63 genes (52%) and 28 genes (15%) of the respective differentially expressed genes. Confirmation rates were imperfect, but clearly above the random baseline of 5% corresponding to the p value threshold 0.05. A bias was expected, because

Fig. 3 Immunohistochemical analysis of FOXP3 and CD8 protein expression in representative example cases of the study cohort. Positive cells were quantified as percentage of all (tumor and stroma) cells. **a** Comparison of ALK-positive tumors with high Treg mRNA marker and ALK-negative tumors with low Treg mRNA marker. The percentage of FOXP3-positive cells was significantly higher in the ALK-positive tumors (mean: 1.84%) than in ALK-negative tumors (mean: 0.96%). **b** Comparison of EGFR-positive tumors with low cytotoxic cell mRNA marker and EGFR-negative tumors with high cytotoxic cell mRNA marker. The percentage of CD8-positive cells was significantly lower in the EGFR-positive tumors (mean: 9%) compared to the EGFR-negative tumors (mean: 40%)



of the limited sample size (only five tumors with ALK fusions in the TCGA cohort), clinical differences between the in-house and the TCGA cohort (later stage vs. earlier stage tumors) and different analysis platforms (NanoString nCounter vs. RNA-Seq).

These were the four most significant gene expression changes detected by the omnibus test in the study cohort (Fig. 5a–d): *VHL* was overexpressed in ALK-positive tumors

compared to both EGFR-positive tumors and ALK/EGFR-negative tumors. *EGFR* was overexpressed in EGFR-positive tumors compared to both ALK-positive tumors and ALK/EGFR-negative tumors. *BAD* showed the highest expression in ALK-positive tumors, an intermediate expression in EGFR-positive tumors and the lowest expression in ALK/EGFR-negative tumors. *VEGFB* showed the same decreasing expression pattern as *BAD*. The overexpression of *EGFR*




Fig. 4 *PD-L1* expression in ALK-positive, EGFR-positive and ALK/EGFR-negative lung adenocarcinoma. **a** Significantly lower *PD-L1* mRNA expression in EGFR-positive tumors compared to ALK-positive tumors, ALK/EGFR-negative tumors that progressed rapidly after ICB and ALK/EGFR-negative tumors that responded durable to

ICB. **b** *PD-L1* mRNA expression and levels of cytotoxic cells correlated positively significantly in ALK-positive and ALK/EGFR-negative tumors, while the correlation was weak and non-significant in EGFR-positive tumors

in EGFR-positive tumors compared to ALK-positive and ALK/EGFR-negative tumors was also found in the TCGA cohort (FC = 2.2, $p = 0.0097$ and FC = 3.1, $p = 3.1E-16$), while we did not detect differential expression of the other three genes.

Analysis of the cytokine–cytokine receptor signaling network

Beyond the estimation of immune cell abundance in the TME, gene expression profiling offers the opportunity to gain insight into the regulation of immune response. Of 294 genes annotated in the KEGG map of cytokines and cytokine receptors, 121 genes (41%) were covered by the used targeted expression assay. Of these, 40 genes (33%) were differentially expressed, 17 between ALK-positive and ALK/EGFR-negative tumors, 16 between EGFR-positive and ALK/EGFR-negative tumors and 26 between ALK-positive and EGFR-positive tumors (Fig. 5e). Compared to ALK/EGFR-negative tumors, five genes were differently expressed in both ALK-positive and EGFR-positive tumors, while twelve genes showed differential expression solely in ALK-positive tumors and eleven genes showed differential expression solely in EGFR-positive tumors (Fig. 5f). We assigned the changes to the map of the interaction of cytokines and receptors (Suppl. 7).

IL2, an interferon that is important for the proliferation of T and B lymphocytes and in particular for the differentiation of CD4+ T cells to T helper cells and Tregs, was overexpressed in ALK-positive and in EGFR-positive tumors compared to ALK/EGFR-negative tumors (FC = 3.0, $p = 0.00013$ and FC = 3.2, $p = 3.0E-05$). *IL11*, an interferon that is known to stimulate the T cell-dependent development of immunoglobulin-producing B cells, was underexpressed in ALK-positive and in EGFR-positive tumors compared to ALK/EGFR-negative tumors (FC = -4.5, $p = 2.7E-05$ and FC = -3.4, $p = 0.00024$). Tumor necrosis factor *TNFRSF4*, suggested to play a role in CD4+ T cell response as well as in T cell-dependent B cell proliferation and differentiation, was strongly overexpressed in ALK-positive tumors compared to ALK/EGFR-negative tumors and compared to EGFR-positive tumors (FC = 5.2, $p = 4.0E-07$ and FC = 7.4, $p = 1.0E-07$). *FASLG*, a cytokine that binds to the receptor FAS that transduces apoptotic signals in cells, was underexpressed in EGFR-positive tumors compared to ALK/EGFR-negative tumors and compared to ALK-positive tumors (FC = -3.5, $p = 2.5E-05$ and FC = -2.6, $p = 0.0033$), an observation possibly related to the lower abundance of cytotoxic cells in EGFR-positive tumors. Prolactin receptor (*PRLR*), which has been suggested as a therapeutic target in subgroups of breast and of prostate cancer [27], was overexpressed in EGFR-positive tumors compared to ALK/EGFR-negative






Fig. 5 Differential gene expression between ALK-positive, EGFR-positive and ALK/EGFR-negative lung adenocarcinoma. **a–d** Expression levels of most significantly differentially expressed genes in omnibus testing: **a** *VHL* was overexpressed in ALK-positive tumors compared to both EGFR-positive tumors and ALK/EGFR-negative tumors. **b** *EGFR* was overexpressed in EGFR-positive tumors compared to both ALK-positive tumors and ALK/EGFR-negative tumors. **c** *BAD* showed the highest expression in ALK-positive tumors, an intermediate expression in EGFR-positive tumors and the lowest expression in ALK/EGFR-negative tumors. **d** *VEGFB* showed the same decreasing expression pattern as *BAD*. **e–f** Analysis of the cytokine–cytokine receptor system: **e** Fold changes of the 40 differentially expressed of the 121 investigated cytokines and cytokine receptors. **f** Twelve genes were differentially expressed exclusively between ALK-positive and ALK/EGFR-negative tumors, eleven genes were differentially expressed exclusively between EGFR-positive and ALK/EGFR-negative tumors, while five genes were differentially expressed in both comparisons. ↑ = upregulation, ↓ = downregulation

tumors and compared to ALK-positive tumors (FC = 3.8, $p = 0.0004$ and FC = 2.6, $p = 0.013$).

Discussion

About 45% to 50% of all NSCLC show a variety of mutually exclusive genetic driver lesions that can be therapeutically exploited. Collectively, EGFR mutations and ALK fusions represent the largest subgroup comprising approx. 20–25%. While these tumors respond well to TKIs, the efficacy of ICB is generally poor despite tremendous trial efforts in the last few years. These observations led to the hypothesis of a poorly immunogenic “immune desert” that prevents successful application of ICB. Early studies of various sample sizes and disease stages investigating immune cell compositions of NSCLC by either immunohistochemistry or flow cytometry revealed the presence of a broad range of infiltrating immune cells including T cells, NK cells, macrophages, B cells, dendritic cells and granulocytes [28–35].

Complementing and extending these studies, we compiled a retrospective cohort of carefully clinically annotated and confirmed ALK- and EGFR-positive NSCLC, molecularly analyzed at the Heidelberg routine diagnostic laboratory [22]. We profiled routine diagnostic formalin-fixed and paraffin-embedded biopsies after mutational analysis by NGS using the NanoString nCounter technology [36]. This technology, which can be directly applied in a routine diagnostic setting and is tissue sparing, facilitates focused analysis of mRNA profiles of 770 genes with fragmented nucleic acids as input material. It enables a multilayered analysis of specific immune cell types as well as expression levels of cytokines, cytokine receptors and other immune genes.

In the first analysis presented here, we identified two groups of immunologically “cold” and “hot” tumors, which were not restricted to a specific subgroup (ALK-positive, EGFR-positive or ALK/EGFR-negative) or

oncogene variant (e.g., ALK V1 vs. V3 or EGFR Ex19del vs. L858R). In the analysis of specific cell populations, different modifications of the TME were detected in ALK-positive and in EGFR-positive tumors compared to ALK/EGFR-negative tumors, respectively: While ALK-positive cases displayed a Treg enriched TME, EGFR-positive cases showed a cytotoxic cell-depleted TME suggesting different mechanisms that abrogate a strong and sustained immune cell response. These two different TMEs appear to be governed by specific immunomodulatory networks, which might be clinically exploitable [37]. Our results confirm other studies analyzing genetic subtypes of NSCLC that found low infiltrates of T cells and CD8+ cells in EGFR-mutant tumors [17, 18]. By contrast, data for ALK-positive NSCLC are highly limited, a few groups identified low CD8 populations in these tumors as well [21, 38]. A more recent study presented reported changes in the immune TME associated with TKI inhibition [39].

For ALK-positive disease, we observed a significant downregulation of *CXCL10* and *CXCL11* negatively influencing general T cell recruitment [40], while at the same time upregulating *CXCL12* [41–43] as well as *CCL22* [44–46] which attract CXCR4+ Tregs. Consistent with the suggested regulation mechanism, T cell levels in the study cohort correlated significantly with *CXCL10* and *CXCL11* ($\rho = 0.44$, $p = 1.6E-06$ and $\rho = 0.47$, $p = 1.1E-07$). Tregs correlated significantly with *CCL22* ($\rho = 0.64$, $p = 2.8E-14$), while the correlation of Tregs and *CXCL12* was not significant. Downregulation of *CXCL10* and *CXCL11* was also observed in EGFR-positive disease.

Comparing ALK-positive and EGFR-positive disease, we noted strong upregulation of *IL10* in ALK-positive tumors. *IL10* is involved in negative feedback mechanisms which decrease the antigen-presenting activity of dendritic cells and inhibit cytotoxic functions and cytokine-release of T and NK lymphocytes [47]. Similarly, pleiotropic *IL6* was upregulated, which was reported to negatively influence T cell response and innate immunity [48, 49]. Notably, the upregulation of *CSF1* and *CCL18*—as identified in the TME of ALK-positive tumors—increases type 2 (M2) tumor-associated macrophages (TAM) which have tumorigenic functions and are known to contribute to immune evasion [50, 51]. *VEGFB* was also upregulated in ALK-positive NSCLC. This might be explained by angiogenic effects but could also be due to potential immunosuppressive effects recently described for VEGF signaling [52, 53]. Interestingly, we identified upregulation of some costimulatory molecules influencing T cell response, including *TNFRSF4* (aka *OX40* [54]). We also observed upregulation of *TNFSF13* (aka *APRIL*), a molecule influencing B cell development. The latter two phenomena may represent an unfruitful

attempt to overcome a generally immune response deprived TME.

The proinflammatory cytokine *IL2* was found to be upregulated in both ALK- and EGFR-positive tumors, while *IL11*, a member of the *IL6* family, was found to be downregulated in both subgroups. *IL2* is known to modulate the development and expansion of Tregs exerting immunosuppressive effects [55]. High *IL11* has been linked to cell proliferation and tumorigenesis in in vitro and in vivo models of NSCLC as well as to unfavorable prognosis [56].

EGFR-positive tumors feature a CD8+ deprived environment that is modulated by downregulation of CCL4, a molecule that supports recruitment of CD103+ dendritic cells which active CD8+ cells [57] as well as downregulated CXCL10, the ligand for CXCR3 on cytotoxic T cells and downregulated CXCL11 negatively modulating CD8+ T cell migration [58, 59]. *IFNGR1* and *IFNGR2* were upregulated, possibly as a compensatory yet non-successful mechanism to overcome impaired CD8+ T cell-mediated immune response.

At the Heidelberg Institute of Pathology, mRNA extracts of lung cancer biopsies are acquired within the routine workflow of lung cancer biopsies and used for gene fusion analysis [22]. For most of the tumors in the study cohort, leftovers of such extract were available and suitable for gene expression profiling. Thus, targeted gene expression represents a tissue-saving method to read out multi-dimensional information on the immune TME from diagnostic lung cancer biopsies.

It is a limitation of gene expression analysis of bulk tissues that expression levels are summarized over all cells in the tissue, while most of the human genes are expressed in various cell types, e.g., in cancer cells and in different other cells in the TME. Thus, in general, the cells types that are causative for the detected gene expression changes cannot be identified from a bulk tissue analysis. Nevertheless, there are transcripts that are expressed by a only a single cell type and conversely there are cell types that can be characterized by the expression of specific marker genes, a methodology that has been exploited to distinguish between 14 immune cell populations in current study.

An advantage of nucleic acid-based technologies is the parallel monitoring of a high number of genes, while spatial resolved technologies such as immunohistochemistry and multispectral imaging usually allow the monitoring of only one or a few genes in parallel and are more difficult to generalize. Thus, nucleic acid-based technologies can be very helpful for screening and knowledge discovery, while spatial resolved technologies should be employed for validation and in-depth cell type-specific analysis. In the current study, we validated an accumulation of Tregs in ALK-positive tumors

and a depletion of CD8+ T cells in EGFR-positive tumors using IHC.

Spatial tumor heterogeneity represents an additional potential limitation for studies in metastatic NSCLC based on a single biopsy of each patient, but this method of sample collection is currently used in the routine molecular pathology.

Collectively, our data revealed two different types of TME modification in ALK- and EGFR-positive NSCLC, respectively, which we term Treg-modulated and CD8-modulated immune TME, each accompanied by a specific characteristic of cytokine signaling. Therefore, tailored therapy strategies will probably be required for oncogene-addicted tumors and we expect detailed profiling of the TME to be instrumental for guiding the selection of appropriate immunomodulatory partners to ICB. Furthermore, our results support the need for exploration of new therapeutic approaches to transform these TME into “hot” states [60]. This may be achievable by opportunistic combinations of ICB with radio- and chemotherapy, or by more subtle, specific approaches that either inhibit specific immunosuppressive agents enriched in “cold” tumors or supplement and boost proinflammatory molecules depleted in “cold” tumors. The detection of significant immune reactivity in oncogene-addicted NSCLC, in contrast the conception of an absolute “immune desert,” suggests that well-aimed use of immunomodulators currently explored in various pre-clinical studies and clinical trials [37, 61] may also hold promise in EGFR- and ALK-positive NSCLC.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00262-021-02981-w>.

Funding Open Access funding enabled and organized by Projekt DEAL. This work was funded by The German Center for Lung Research (Deutsches Zentrum für Lungenforschung, DZL) and by Roche Pharma.

Declarations

Conflict of interest Dr. Budczies reports grants from German Cancer Aid, outside the submitted work. Dr. Kirchner, Mr. Kluck, Ms. Glade, Dr. Allgäuer, Dr. Kriegsmann, Dr. Winter, Dr. Goldmann, Dr. Wermke have nothing to disclose. Dr. Kazdal reports personal fees from Pfizer Pharma GmbH, outside the submitted work. Dr. Herth reports personal fees from Schering-Plough, personal fees from Pfizer, personal fees from Basilea, personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Roche, personal fees from Astellas, personal fees from Gilead, personal fees from MSD, personal fees from Lilly, personal fees from Intermune, personal fees from Fresenius, personal fees from Essex, personal fees from AstraZeneca, personal fees from Bracco, personal fees from MEDA Pharma, personal fees from Chiesi, personal fees from Siemens, personal fees from Covidien, personal fees from Pierre Fabre, personal fees from Grifols, personal fees from Bayer, personal fees from Siemens, personal fees from Pfizer, personal fees from MeVis, personal fees from Boehringer Ingelheim, personal fees from German Cancer for Lung Research, out-

side the submitted work; In addition, Dr. Herth has a patent Method and Device For Representing the Microstructure of the Lungs. IPC8 Class: AA61B5055FI, PAN: 20080208038 pending. Dr. Herth reports personal fees from Schering-Plough, personal fees from Pfizer, personal fees from Basilea, personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Roche, personal fees from Astellas, personal fees from Gilead, personal fees from MSD, personal fees from Lilly, personal fees from Intermune, personal fees from Fresenius, personal fees from Essex, personal fees from AstraZeneca, personal fees from Bracco, personal fees from MEDA Pharma, personal fees from Chiesi, personal fees from Siemens, personal fees from Covidien, personal fees from Pierre Fabre, personal fees from Grifols, personal fees from Bayer, personal fees from Siemens, personal fees from Pfizer, personal fees from MeVis, personal fees from Boehringer Ingelheim, personal fees from German Cancer for Lung Research, outside the submitted work. Dr. Meister reports grants from German Center for Lung Research (DZL), during the conduct of the study. Dr. Muley reports grants and non-financial support from Roche Diagnostics GmbH, Penzberg, Germany, outside the submitted work; In addition, Dr. Muley has a patent WO2019158460 pending, a patent WO2019211418 pending, a patent WO2019215223 pending, a patent EP3391053 issued and a patent EP3365679 pending. Dr. Fröhling reports personal fees from Amgen, grants from AstraZeneca, personal fees from Bayer, personal fees from Eli Lilly, grants from Pfizer, grants and personal fees from PharmaMar, personal fees from Roche, outside the submitted work. Dr. Waller is a consultant/advisory board member for Mylan Inc. Dr. Reck reports personal fees from Amgen, personal fees from AstraZeneca, personal fees from BMS, personal fees from Boehringer Ingelheim, personal fees from Lilly, personal fees from Merck, personal fees from MSD, personal fees from Novartis, personal fees from Pfizer, personal fees from Roche, personal fees from Samsung, outside the submitted work. Dr. Peters reports personal fees from Abbvie, personal fees from Amgen, personal fees from AstraZeneca, personal fees from Bayer, personal fees from Biocartis, personal fees from Boehringer Ingelheim, personal fees from Bistol-Myers Squibb, personal fees from Clovis, personal fees from Daiichi Sankyo, personal fees from Debiopharm, personal fees from Eli Lilly, personal fees from F. Hoffmann-La Roche, personal fees from Foundation Medicine, personal fees from Illumina, personal fees from Janssen, personal fees from Merck Sharp and Dohme, personal fees from Merck Serono, personal fees from Merrimack, personal fees from Novartis, personal fees from Pharma Mar, personal fees from Pfizer, personal fees from Regeneron, personal fees from Sanofi, personal fees from Seattle Genetics and Takeda, personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Bristol-Myers Squibb, personal fees from Eli Lilly, personal fees from F. Hoffmann-La Roche, personal fees from Merck Sharp and Dohme, personal fees from Novartis, personal fees from Pfizer, personal fees from Takeda, non-financial support from Sponsored by Amgen, non-financial support from AstraZeneca, non-financial support from Boehringer Ingelheim, non-financial support from Bristol-Myers Squibb, non-financial support from Clovis, non-financial support from F. Hoffmann-La Roche, non-financial support from Illumina, non-financial support from Merck Sharp and Dohme, non-financial support from Merck Serono, non-financial support from Novartis, non-financial support from Pfizer, non-financial support from Sanofi, personal fees from Bioinvent, outside the submitted work. All fees to Institution. Dr. Schirmacher reports grants from QuIP, during the conduct of the study; grants and personal fees from BMS, grants and personal fees from MSD, grants and personal fees from Roche, grants and personal fees from AstraZeneca, grants and personal fees from Novartis, personal fees from Chugai, personal fees from AbbVie, grants from Sanofi-Aventis, personal fees from Ipsen, grants and personal fees from Pfizer, grants from Illumina, grants from Thermo Fisher, outside the submitted work. Dr. Thomas reports personal fees from AbbVie, grants, personal fees and non-financial support from BMS, personal fees and non-financial sup-

port from Boehringer, grants and personal fees from Celgene, personal fees from Lilly, personal fees and non-financial support from MSD, personal fees and non-financial support from Novartis, grants and personal fees from Roche, personal fees from Takeda, grants from AstraZeneca, outside the submitted work. Dr. Christopoulos reports grants and personal fees from Novartis, grants and personal fees from Roche, grants and personal fees from AstraZeneca, personal fees from Pfizer, grants and personal fees from Takeda, personal fees from Chugai, personal fees from Boehringer, outside the submitted work. Dr. Stenzinger reports personal fees from AstraZeneca, grants and personal fees from Bayer, grants and personal fees from BMS, personal fees from MSD, personal fees from Takeda, personal fees from Seattle Genetics, grants from Chugai, personal fees from Novartis, personal fees from Illumina, personal fees from Thermo Fisher, personal fees from Eli Lilly, personal fees from Takeda, outside the submitted work.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References


1. Howlader N, Noone AM, Krapcho M, et al (2020) SEER cancer statistics review (CSR) 1975–2017. National Cancer Institute
2. Reck M, Rabe KF (2017) Precision diagnosis and treatment for advanced non-small-cell lung cancer. *N Engl J Med* 377:849–861
3. Planchard D, Popat S, Kerr K et al (2018) Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 29:iv192–iv237
4. Garon EB, Wolf B, Lisberg A et al (2015) Prior TKI Therapy in NSCLC EGFR mutant patients associates with lack of response to Anti-PD-1 treatment. *J Thorac Oncol* 10:269
5. Lisberg A, Cummings A, Goldman JW et al (2018) A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. *J Thorac Oncol* 13:1138–1145
6. Gettinger S, Rizvi NA, Chow LQ et al (2016) Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. *J Clin Oncol* 34:2980–2987
7. Rizvi NA, Hellmann MD, Brahmer JR et al (2016) Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. *J Clin Oncol* 34:2969–2979
8. Creelan BC, Yeh T, Kim S-W et al (2019) Phase I study of gefitinib (G) plus durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations. *Ann Oncol* 30:ii31–ii37
9. Yang JC, Gadgeel SM, Sequist LV et al (2019) Pembrolizumab in combination with erlotinib or gefitinib as first-line therapy for advanced NSCLC with sensitizing EGFR mutation. *J Thorac Oncol* 14:553–559

10. Mok TSK, Socinski MA, Reck M et al (2019) IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. *Ann Oncol* 29:ix177–ix178
11. Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N Engl J Med* 378:2288–2301
12. Offin M, Rizvi H, Tenet M et al (2019) Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. *Clin Cancer Res* 25:1063–1069
13. Singal G, Miller PG, Agarwala V et al (2019) Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database. *JAMA* 321:1391–1399
14. Zhang N, Zeng Y, Du W et al (2016) The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. *Int J Oncol* 49:1360–1368
15. Chen N, Fang W, Zhan J et al (2015) Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. *J Thorac Oncol* 10:910–923
16. Mazzaschi G, Madeddu D, Falco A et al (2018) Low PD-1 expression in cytotoxic CD8+ tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value. *Clin Cancer Res* 24:407–419
17. Toki MI, Mani N, Smithy JW et al (2018) Immune marker profiling and programmed death ligand 1 expression across NSCLC mutations. *J Thorac Oncol* 13:1884–1896
18. Dong ZY, Zhang JT, Liu SY et al (2017) EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. *Oncoimmunology* 6:e1356145
19. Haratani K, Hayashi H, Tanaka T et al (2017) Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. *Ann Oncol* 28:1532–1539
20. Liu L, Mayes PA, Eastman S et al (2015) The BRAF and MEK Inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. *Clin Cancer Res* 21:1639–1651
21. Gainor JF, Shaw AT, Sequist LV et al (2016) EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. *Clin Cancer Res* 22:4585–4593
22. Volckmar AL, Leichsenring J, Kirchner M et al (2019) Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: analysis of the first 3000 Heidelberg cases. *Int J Cancer* 145:649–661
23. Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgäuer M, Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Fröhling S, Peters S, Seliger B, Schirmacher P, Thomas M, Christopoulos P, Stenzinger A (2021) A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. *Oncoimmunology* 10(1):1860586. <https://doi.org/10.1080/2162402X.2020.1860586>
24. Hu X, Wang Q, Tang M et al (2018) TumorFusions: an integrative resource for cancer-associated transcript fusions. *Nucleic Acids Res* 46:D1144–D1149
25. Danaher P, Warren S, Dennis L et al (2017) Gene expression markers of tumor infiltrating leukocytes. *J Immunother Cancer* 5:18
26. Kanehisa M, Sato Y (2020) KEGG Mapper for inferring cellular functions from protein sequences. *Protein Sci* 29:28–35
27. O'Sullivan CC, Bates SE (2016) Targeting prolactin receptor (PRLR) signaling in PRLR-positive breast and prostate cancer. *Oncologist* 21:523–526
28. Banat GA, Tretyn A, Pullamsetti SS et al (2015) Immune and inflammatory cell composition of human lung cancer stroma. *PLoS ONE* 10:e0139073
29. Al-Shibli KI, Donnem T, Al-Saad S et al (2008) Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. *Clin Cancer Res* 14:5220–5227
30. Ohri CM, Shikotra A, Green RH et al (2009) Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. *Eur Respir J* 33:118–126
31. Al-Shibli K, Al-Saad S, Donnem T et al (2009) The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. *Histopathology* 55:301–312
32. Schalper KA, Brown J, Carvajal-Hausdorf D et al (2015) Objective measurement and clinical significance of TILs in non-small cell lung cancer. *J Natl Cancer Inst*. <https://doi.org/10.1093/jnci/dju435>
33. Ganesan AP, Johansson M, Ruffell B et al (2013) Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. *J Immunol* 191:2009–2017
34. Lizotte PH, Ivanova EV, Awad MM et al (2016) Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. *JCI Insight* 1:e89014
35. Kargl J, Busch SE, Yang GH et al (2017) Neutrophils dominate the immune cell composition in non-small cell lung cancer. *Nat Commun* 8:14381
36. Talla SB, Rempel E, Endris V et al (2020) Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: performance comparison of the nanostring ncounter technology with targeted RNA sequencing. *Genes Chromosomes Cancer* 59:406–416
37. Berraondo P, Sanmamed MF, Ochoa MC et al (2019) Cytokines in clinical cancer immunotherapy. *Br J Cancer* 120:6–15
38. Liu SY, Dong ZY, Wu SP et al (2018) Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. *Lung Cancer* 125:86–92
39. Isomoto K, Haratani K, Hayashi H et al (2020) Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer. *Clin Cancer Res* 26:2037–2046
40. Vilgelm AE, Richmond A (2019) Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy. *Front Immunol* 10:333
41. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. *Nat Rev Cancer* 5:263–274
42. Zou W, Machelon V, Coulomb-L'Hermin A et al (2001) Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. *Nat Med* 7:1339–1346
43. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. *Nat Rev Immunol* 6:295–307
44. Martinenaite E, Munir Ahmad S, Hansen M et al (2016) CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment. *Oncoimmunology* 5:e1238541
45. Gobert M, Treilleux I, Bendriss-Vermare N et al (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. *Cancer Res* 69:2000–2009
46. Rapp M, Wintergerst MWM, Kunz WG et al (2019) CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes. *J Exp Med* 216:1170–1181

47. O'Garra A, Vieira P (2007) T(H)1 cells control themselves by producing interleukin-10. *Nat Rev Immunol* 7:425–428
48. Tsukamoto H, Fujieda K, Senju S et al (2018) Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity. *Cancer Sci* 109:523–530
49. Somasundaram A, Cillo A, Oliveri L et al (2019) IL-6, IL-8 drive LAG3/PD1 immune suppression on effector and naïve, peripheral blood CD8+ T cells in cancer patients. *J Immunol* 202(1 Supplement):195.9
50. Cannarile MA, Weisser M, Jacob W et al (2017) Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. *J Immunother Cancer* 5:53
51. Chen J, Yao Y, Gong C et al (2011) CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PTPN23. *Cancer Cell* 19:541–555
52. Voron T, Colussi O, Marcheteau E et al (2015) VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. *J Exp Med* 212:139–148
53. Lapeyre-Prost A, Terme M, Pernot S et al (2017) Immunomodulatory activity of VEGF in cancer. *Int Rev Cell Mol Biol* 330:295–342
54. Gough MJ, Ruby CE, Redmond WL et al (2008) OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. *Cancer Res* 68:5206–5215
55. Nelson BH (2004) IL-2, regulatory T cells, and tolerance. *J Immunol* 172:3983–3988
56. Zhao M, Liu Y, Liu R et al (2018) Upregulation of IL-11, an IL-6 family cytokine, promotes tumor progression and correlates with poor prognosis in non-small cell lung cancer. *Cell Physiol Biochem* 45:2213–2224
57. Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. *Nature* 523:231–235
58. Christensen JE, de Lemos C, Moos T et al (2006) CXCL10 is the key ligand for CXCR3 on CD8+ effector T cells involved in immune surveillance of the lymphocytic choriomeningitis virus-infected central nervous system. *J Immunol* 176:4235–4243
59. Gao Q, Wang S, Chen X et al (2019) Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. *J Immunother Cancer* 7:42
60. Seliger B (2019) Combinatorial approaches with checkpoint inhibitors to enhance anti-tumor immunity. *Front Immunol* 10:999
61. Tang J, Shalabi A, Hubbard-Lucey VM (2018) Comprehensive analysis of the clinical immuno-oncology landscape. *Ann Oncol* 29:84–91

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Jan Budczies^{1,2,3}  · Martina Kirchner¹ · Klaus Kluck^{1,2} · Daniel Kazdal^{1,3} · Julia Glade¹ · Michael Allgauer¹ · Mark Kriegsmann^{1,3} · Claus-Peter Heuβel^{3,4,5} · Felix J. Herth^{3,6} · Hauke Winter^{3,7} · Michael Meister^{3,8} · Thomas Muley^{3,8} · Torsten Goldmann^{9,10} · Stefan Fröhling^{2,11} · Martin Wermke¹² · Cornelius F. Waller¹³ · Amanda Tufman¹⁴ · Martin Reck^{10,15} · Solange Peters¹⁶ · Peter Schirmacher^{1,2} · Michael Thomas^{3,17} · Petros Christopoulos^{3,17} · Albrecht Stenzinger^{1,2,3}

¹ Institute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, Heidelberg, Germany

² German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany

³ Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany

⁴ Department of Diagnostic and Interventional Radiology With Nuclear Medicine, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany

⁵ Department of Diagnostic and Interventional Radiology, University Hospital, Heidelberg, Germany

⁶ Department of Pneumology, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany

⁷ Department of Thoracic Surgery, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany

⁸ Translational Research Unit, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany

⁹ Pathology of the University Medical Center Schleswig-Holstein (UKSH), Campus Lübeck and the Research Center Borstel, Borstel, Germany

¹⁰ Airway Research Center North (ARCN), Member of German Center of Lung Research (DZL), Giessen, Germany

¹¹ Department of Translational Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany

¹² Department of Thoracic Oncology, Dresden University Hospital, Dresden, Germany

¹³ Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg, Freiburg, Germany

¹⁴ Division of Respiratory Medicine and Thoracic Oncology, Department of Internal Medicine V and Thoracic Oncology Centre Munich, Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), University of Munich (LMU), Munich, Germany

¹⁵ Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Grosshansdorf, Germany

¹⁶ Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne University, Lausanne, Switzerland

¹⁷ Department of Thoracic Oncology, Thoraxklinik At Heidelberg University Hospital, Heidelberg, Germany